Nektar Therapeutics (NASDAQ:NKTR)’s traded shares stood at 1.32 million during the last session, with the company’s beta value hitting 0.90. At the close of trading, the stock’s price was $0.93, to imply an increase of 5.55% or $0.04 in intraday trading. The NKTR share’s 52-week high remains $1.12, putting it -20.43% down since that peak but still an impressive 55.91% since price per share fell to its 52-week low of $0.41. The company has a valuation of $171.54M, with an average of 1.03 million shares in intraday trading volume over the past 10 days and average of 1.62 million shares over the past 3 months.
Nektar Therapeutics (NASDAQ:NKTR) trade information
After registering a 5.55% upside in the last session, Nektar Therapeutics (NKTR) has traded red over the past five days. The stock hit a weekly high of 0.9400, jumping 5.55% in its intraday price action. The 5-day price performance for the stock is 4.11%, and 29.75% over 30 days. With these gigs, the year-to-date price performance is 65.35%. Short interest in Nektar Therapeutics (NASDAQ:NKTR) saw shorts transact 2.51 million shares and set a 0.93 days time to cover.
Nektar Therapeutics (NKTR) estimates and forecasts
Looking at statistics comparing Nektar Therapeutics share performance against respective industry, we note that the company has outperformed competitors. Nektar Therapeutics (NKTR) shares are 55.23% up over the last 6 months, with its year-to-date growth rate higher than industry average at 32.41% against 8.20%. Revenue is forecast to grow 74.00% this quarter before jumping 29.60% for the next one. The rating firms project that company’s revenue will shrink -25.10% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $15.34 million. Meanwhile, for the quarter ending Jun 2024, a total of 3 analyst(s) estimate revenue growth to $15.34 million.
NKTR Dividends
Nektar Therapeutics has its next earnings report out between May 07 and May 13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Nektar Therapeutics has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Nektar Therapeutics insiders hold 1.01% of total outstanding shares, with institutional holders owning 67.40% of the shares at 68.09% float percentage. In total, 67.40% institutions holds shares in the company, led by Deep Track Capital, Lp. As of Jun 29, 2023, the company held over 17.97 million shares (or 9.45% of shares), all amounting to roughly $10.34 million.
The next major institution holding the largest number of shares is Vanguard Group Inc with 12.06 million shares, or about 6.34% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $6.93 million.
We also have Vanguard Total Stock Market Index Fund and Primecap Odyssey Aggressive Growth Fund as the top two Mutual Funds with the largest holdings of the Nektar Therapeutics (NKTR) shares. Going by data provided on Jun 29, 2023, Vanguard Total Stock Market Index Fund holds roughly 5.85 million shares. This is just over 3.08% of the total shares, with a market valuation of $3.36 million. Data from the same date shows that the other fund manager holds a little less at 4.25 million, or 2.24% of the shares, all valued at about 2.28 million.
